0001567619-23-004608.txt : 20230307 0001567619-23-004608.hdr.sgml : 20230307 20230307171500 ACCESSION NUMBER: 0001567619-23-004608 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220610 FILED AS OF DATE: 20230307 DATE AS OF CHANGE: 20230307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cambrian BioPharma Inc CENTRAL INDEX KEY: 0001797409 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 23713675 BUSINESS ADDRESS: STREET 1: 228 PARK AVENUE S. STREET 2: #66643 CITY: NEW YORK STATE: NY ZIP: 10003 BUSINESS PHONE: (516) 962-3186 MAIL ADDRESS: STREET 1: 228 PARK AVENUE S. STREET 2: #66643 CITY: NEW YORK STATE: NY ZIP: 10003 FORMER NAME: FORMER CONFORMED NAME: Cambrian BioPharma Inc. DATE OF NAME CHANGE: 20191219 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 620 PROFESSIONAL DRIVE CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 620 PROFESSIONAL DRIVE CITY: GAITHERSBURG STATE: MD ZIP: 20879 4/A 1 doc1.xml FORM 4/A X0306 4/A 2022-06-10 2022-06-14 0 0001829802 Sensei Biotherapeutics, Inc. SNSE 0001797409 Cambrian BioPharma Inc 228 PARK AVENUE S. #66643 NEW YORK NY 10003 0 0 1 0 Restricted Stock Unit Grant 2022-06-10 4 A 0 4466 0 A 5235956 D Stock Option (right to buy) 2.05 2022-06-10 4 A 0 14550 0 A 2032-06-09 Common Stock 14550 14550 D These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer through such vesting date. These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the James Peyer's continuous service with the Issuer through such vesting date. Amendment filed solely to correct the number of shares owned. Cambrian BioPharma Inc, by: /s/ James Peyer 2023-03-07